UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial

European journal of cancer (1990), 2016-01, Vol.53, p.155-162

2016

Volltextzugriff (PDF)

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Annals of oncology, 2013-09, Vol.24 (9), p.2335-2341

2013

Volltextzugriff (PDF)

Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer

Annals of oncology, 2009-06, Vol.20 (6), p.1057-1061

2009

Volltextzugriff (PDF)

Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases

European journal of surgical oncology, 2018-07, Vol.44 (7), p.983-990

2018

Volltextzugriff (PDF)

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study

ESMO open, 2022-06, Vol.7 (3), p.100427-100427, Article 100427

2022

Volltextzugriff (PDF)

Molecular treatment stratification in second-line treatment of pancreatic adenocarcinoma: PePaCaKa-001

ANNALS OF ONCOLOGY, 2018-09, Vol.29, p.vi31-vi31

2018

Volltextzugriff (PDF)

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

Annals of oncology, 2016-01, Vol.27 (1), p.140-147

2016

Volltextzugriff (PDF)

A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer

Annals of oncology, 2010-05, Vol.21 (5), p.1020-1026

2010

Volltextzugriff (PDF)

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer—results from the RAPIDO trial

ESMO open, 2023-04, Vol.8 (2), p.101158-101158, Article 101158

2023

Volltextzugriff (PDF)

Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors

European journal of cancer (1990), 2024-05, Vol.202, p.114010-114010, Article 114010

2024

Volltextzugriff (PDF)

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer

Annals of oncology, 2002-12, Vol.13 (12), p.1868-1873

2002

Volltextzugriff (PDF)

Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer

ESMO Gastrointestinal Oncology, 2024-09, Vol.5, p.100070, Article 100070

2024

Volltextzugriff (PDF)

Preoperative short-course radiation therapy with PROtons compared to photons in high-risk RECTal cancer (PRORECT): Initial dosimetric experience

Clinical and translational radiation oncology, 2023-03, Vol.39, p.100562-100562, Article 100562

2023

Volltextzugriff (PDF)

Ga733/EpCAM as a Target for Passive and Active Specific Immunotherapy in Patients with Colorectal Carcinoma

Annals of the New York Academy of Sciences, 2000-06, Vol.910 (1), p.254-262

2000

Volltextzugriff (PDF)

Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression

Cancer Immunology, Immunotherapy, 2002-07, Vol.51 (5), p.255-262

2002

Volltextzugriff (PDF)

Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study

Annals of oncology, 2010-05, Vol.21 (5), p.1127-1128

2010

Volltextzugriff (PDF)

Incidence of GM-CSF Antibodies in Cancer Patients Receiving GM-CSF for Immunostimulation

Clinical immunology (Orlando, Fla.), 2001-04, Vol.99 (1), p.65-74

2001

Volltextzugriff (PDF)

Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer

Radiotherapy and oncology, 2004-02, Vol.70 (2), p.171-175

2004

Volltextzugriff (PDF)

Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial

BJS open, 2021-11, Vol.5 (6)

2021

Volltextzugriff (PDF)

Multiple Primary Malignant Tumors in a National Cancer Registry: Reliability of Reporting

Acta oncologica, 1997, Vol.36 (5), p.465-469

1997

Volltextzugriff (PDF)

Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis colon cancer families

Cancer research (Chicago, Ill.), 1995-12, Vol.55 (24), p.6092-6096

1995

Volltextzugriff (PDF)

Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor

Clinical cancer research, 1998-08, Vol.4 (8), p.1921-1929

1998

Volltextzugriff (PDF)

Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol

PloS one, 2024-03, Vol.19 (3), p.e0294018-e0294018

2024

Volltextzugriff (PDF)

induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab). II: Is induction of anti-idiotype reactive T cells (T3) of importance of tumor response to mAb therapy ?

Cancer Immunology, Immunotherapy, 1994-05, Vol.38 (3), p.149-159

1994

Volltextzugriff (PDF)

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A

Cancer Immunology, Immunotherapy, 1996-02, Vol.42 (2), p.81-87

1996

Volltextzugriff (PDF)

1 – 25 von 155

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(123)

Publikationsform

Artikel
(141)
Tagungsberichte
(14)

Sprache

Englisch
(154)
Schwedisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(99)
Science & Technology
(97)
Life Sciences & Biomedicine
(95)
Medicin Och Hälsovetenskap
(88)
Male
(69)
Oncology
(69)
Female
(66)
Middle Aged
(60)
Biological And Medical Sciences
(58)
Aged
(55)
Medical Sciences
(55)
Adult
(48)
Pharmacology. Drug Treatments
(39)
Antineoplastic Agents
(36)
Antibodies, Monoclonal - Therapeutic Use
(32)
Immunotherapy
(31)
Tumors
(27)
Colorectal Neoplasms - Immunology
(26)
Colorectal Neoplasms - Therapy
(23)
Aged, 80 And Over
(21)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer

Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study

Molecular treatment stratification in second-line treatment of pancreatic adenocarcinoma: PePaCaKa-001

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer—results from the RAPIDO trial

Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors

Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer

Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer

Preoperative short-course radiation therapy with PROtons compared to photons in high-risk RECTal cancer (PRORECT): Initial dosimetric experience

Ga733/EpCAM as a Target for Passive and Active Specific Immunotherapy in Patients with Colorectal Carcinoma

Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression

Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study

Incidence of GM-CSF Antibodies in Cancer Patients Receiving GM-CSF for Immunostimulation

Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer

Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial

Multiple Primary Malignant Tumors in a National Cancer Registry: Reliability of Reporting

Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis colon cancer families

Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor

Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol

induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab). II: Is induction of anti-idiotype reactive T cells (T3) of importance of tumor response to mAb therapy ?

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A

Suchergebnisse filtern